uniQure (NASDAQ:QURE) Given Average Recommendation of "Moderate Buy" by Analysts

uniQure (NASDAQ:QURE - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven brokerages that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $37.82.

Several analysts have issued reports on QURE shares. Royal Bank of Canada restated an "outperform" rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company decreased their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. Chardan Capital reiterated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research note on Monday. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research note on Monday, April 21st. Finally, StockNews.com upgraded uniQure to a "sell" rating in a research note on Tuesday, March 11th.

Insider Activity

In other news, CFO Christian Klemt sold 10,438 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares of the company's stock, valued at approximately $2,240,441.70. The trade was a 4.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at approximately $6,703,461.66. This trade represents a 4.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,830 shares of company stock valued at $961,401. Insiders own 4.74% of the company's stock.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently made changes to their positions in the business. Twin Tree Management LP purchased a new position in uniQure during the 4th quarter valued at $77,000. FNY Investment Advisers LLC purchased a new position in shares of uniQure during the fourth quarter valued at about $88,000. ADAR1 Capital Management LLC bought a new position in uniQure in the fourth quarter worth about $177,000. Mraz Amerine & Associates Inc. purchased a new stake in uniQure in the first quarter worth about $106,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after buying an additional 969 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Trading Down 2.6%

Shares of uniQure stock opened at $12.81 on Wednesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock has a 50 day moving average price of $12.25 and a two-hundred day moving average price of $12.18. The stock has a market capitalization of $701.68 million, a PE ratio of -2.58 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.